Product nameAnti-FOXO1A (phospho S322 + S325) antibody
See all FOXO1A primary antibodies
DescriptionRabbit polyclonal to FOXO1A (phospho S322 + S325)
Specificityab60945 detects endogenous levels of FOXO1A only when phosphorylated at serine 322 and serine 325.
Tested applicationsSuitable for: ELISA, WBmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat
Synthetic phosphopeptide derived from human FOXO1A around the phosphorylation site of serine 322 and serine 325 (N-A-SP-T-I-SP-G-R).
- NIH 3T3 cell extracts treated with Wortmannin (40nM, 24hours).
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Without Mg2+ and Ca2+
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab60945 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
Our Abpromise guarantee covers the use of ab60945 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 90 kDa (predicted molecular weight: 70 kDa).|
FunctionTranscription factor which acts as a regulator of cell responses to oxidative stress. In the presence of KIRT1, mediates down-regulation of cyclin D1 and up-regulation of CDKN1B levels which are required for cell transition from proliferative growth to quiescence.
Involvement in diseaseDefects in FOXO1 are a cause of rhabdomyosarcoma type 2 (RMS2) [MIM:268220]. It is a form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchimal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas. Note=Chromosomal aberrations involving FOXO1 are found in rhabdomyosarcoma. Translocation (2;13)(q35;q14) with PAX3; translocation t(1;13)(p36;q14) with PAX7. The resulting protein is a transcriptional activator.
Sequence similaritiesContains 1 fork-head DNA-binding domain.
modificationsPhosphorylated by AKT1; insulin-induced (By similarity). IGF1 rapidly induces phosphorylation of Ser-256, Thr-24, and Ser-319. Phosphorylation of Ser-256 decreases DNA-binding activity and promotes the phosphorylation of Thr-24, and Ser-319, permitting phosphorylation of Ser-322 and Ser-325, probably by CK1, leading to nuclear exclusion and loss of function. Phosphorylation of Ser-329 is independent of IGF1 and leads to reduced function. Phosphorylated upon DNA damage, probably by ATM or ATR.
Cellular localizationCytoplasm. Nucleus. Shuttles between cytoplasm and nucleus.
- Information by UniProt
- FKH 1 antibody
- FKH1 antibody
- FKHR antibody
All lanes : Anti-FOXO1A (phospho S322 + S325) antibody (ab60945) at 1/500 dilution
Lane 1 : NIH 3T3 cell extracts treated with Wortmannin (40nM, 24hours)
Lane 2 : NIH 3T3 cell extracts treated with Wortmannin (40nM, 24hours) with immunising peptide
Predicted band size: 70 kDa
Observed band size: 90 kDa why is the actual band size different from the predicted?
ab60945 has not yet been referenced specifically in any publications.